UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (965) 965
science & technology (927) 927
life sciences & biomedicine (893) 893
carbazoles - therapeutic use (724) 724
male (686) 686
female (636) 636
propanolamines - therapeutic use (518) 518
middle aged (445) 445
carbazoles - adverse effects (425) 425
adrenergic beta-antagonists - therapeutic use (395) 395
aged (346) 346
carvedilol (339) 339
animals (324) 324
carbazoles - pharmacology (312) 312
adult (290) 290
carbazoles - administration & dosage (290) 290
heart failure - drug therapy (278) 278
cardiovascular system & cardiology (277) 277
treatment outcome (275) 275
propanolamines - adverse effects (264) 264
cardiac & cardiovascular systems (245) 245
pharmacology & pharmacy (210) 210
adrenergic beta-antagonists - adverse effects (209) 209
heart failure (205) 205
propanolamines - administration & dosage (180) 180
double-blind method (173) 173
abridged index medicus (152) 152
drug therapy (147) 147
propanolamines - pharmacology (141) 141
dose-response relationship, drug (133) 133
adrenergic beta-antagonists - administration & dosage (123) 123
blood pressure - drug effects (121) 121
hypertension - drug therapy (120) 120
metoprolol - therapeutic use (114) 114
heart rate - drug effects (113) 113
heart failure - physiopathology (101) 101
adrenergic beta-antagonists - pharmacology (99) 99
care and treatment (99) 99
medicine & public health (98) 98
carbazoles - pharmacokinetics (96) 96
oncology (94) 94
time factors (94) 94
antihypertensive agents - therapeutic use (92) 92
prospective studies (92) 92
rats (91) 91
drug therapy, combination (89) 89
analysis (86) 86
aged, 80 and over (85) 85
randomized controlled trials as topic (80) 80
carbazoles (74) 74
follow-up studies (74) 74
chronic disease (72) 72
heart failure - mortality (71) 71
research (71) 71
general & internal medicine (70) 70
vasodilator agents - therapeutic use (69) 69
beta blockers (68) 68
hypertension (67) 67
medicine, general & internal (67) 67
neurosciences & neurology (65) 65
mice (63) 63
drug administration schedule (62) 62
cardiology (61) 61
migraine disorders - drug therapy (60) 60
veterinary sciences (60) 60
stroke volume - drug effects (59) 59
cardiovascular (58) 58
clinical trials (58) 58
hemodynamics - drug effects (58) 58
lung neoplasms - drug therapy (57) 57
clinical trials as topic (56) 56
health aspects (56) 56
piperidines - therapeutic use (54) 54
administration, oral (53) 53
cross-over studies (53) 53
dogs (53) 53
propanolamines - pharmacokinetics (53) 53
ventricular dysfunction, left - drug therapy (53) 53
adolescent (52) 52
carcinoma, non-small-cell lung - drug therapy (52) 52
cardiac patients (51) 51
hypertension - physiopathology (51) 51
ventricular function, left - drug effects (51) 51
antihypertensive agents - adverse effects (50) 50
clinical neurology (50) 50
frovatriptan (50) 50
risk factors (50) 50
retrospective studies (49) 49
migraine (48) 48
peripheral vascular disease (46) 46
mortality (45) 45
neurosciences (45) 45
severity of illness index (45) 45
antineoplastic agents - adverse effects (44) 44
cancer (44) 44
metoprolol (44) 44
toxicology (42) 42
young adult (42) 42
carbazoles - chemistry (41) 41
cardiomyopathy, dilated - drug therapy (41) 41
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1221) 1221
German (28) 28
Russian (11) 11
Japanese (6) 6
French (5) 5
Italian (4) 4
Chinese (3) 3
Danish (3) 3
Portuguese (3) 3
Spanish (2) 2
Turkish (2) 2
Czech (1) 1
Hungarian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 08/2017, Volume 377, Issue 9, pp. 829 - 838
... with a 50% maximum inhibitory concentration of 1.9 nmol per liter in enzymatic analyses and with activity against the effects of several ALK mutations that confer... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Follow-Up Studies | Lung Neoplasms - mortality | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Central Nervous System Neoplasms - secondary | Young Adult | Pyridines - adverse effects | Anaplastic Lymphoma Kinase | Antineoplastic Agents - adverse effects | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Receptor Protein-Tyrosine Kinases - analysis | Pyrazoles - adverse effects | Pyridines - therapeutic use | Crizotinib | Carbazoles - adverse effects | Kaplan-Meier Estimate | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Animals | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Piperidines - adverse effects | Intention to Treat Analysis | Carbazoles - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Central Nervous System Neoplasms - drug therapy | Drugs | Care and treatment | Analysis | Comparative analysis | Lung cancer, Non-small cell | Health aspects | Systemic diseases | Toxicity | Lung cancer | Central nervous system | Non-small cell lung carcinoma | Oncology | Nervous system | Metastasis | Radiation therapy | Patients | Lymphoma | Cancer therapies | Survival | Mutation | Protein-tyrosine kinase | Drug dosages | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
The Lancet (British edition), ISSN 0140-6736, 07/2017, Volume 390, Issue 10089, pp. 29 - 39
Summary Background Alectinib, a potent, highly selective, CNS-active inhibitor of anaplastic lymphoma kinase (ALK), showed promising efficacy and tolerability... 
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Single-Blind Method | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Piperidines - blood | Brain Neoplasms - secondary | Pyridines - adverse effects | Carcinoma, Non-Small-Cell Lung - secondary | Neoplasm Grading | Antineoplastic Agents - adverse effects | Pyrazoles - blood | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Carbazoles - blood | Pyrazoles - adverse effects | Pyridines - therapeutic use | Carcinoma, Non-Small-Cell Lung - pathology | Carbazoles - adverse effects | Lung Neoplasms - enzymology | Kaplan-Meier Estimate | Receptor Protein-Tyrosine Kinases - metabolism | Protein Kinase Inhibitors - blood | Pyridines - blood | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Piperidines - adverse effects | Antineoplastic Agents - blood | Aged | Carbazoles - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Medical colleges | Respiratory agents | Care and treatment | Lymphomas | Lung cancer, Non-small cell | Product development | Pharmaceutical industry | Analysis | Toxicity | Funding | Lung cancer | Central nervous system | Metastasis | Kinases | Evidence-based medicine | Recruitment | Motivation | Audio frequencies | Safety | Toxic diseases | Drug dosages | Protein-tyrosine kinase | Effectiveness | Cut-off | Data processing | Group dynamics | Patients | Survival | Lymphoma | Chemotherapy | Inhibitors | Interactive systems | Death | Mutation | Cancer | Pharmaceuticals | Index Medicus | Abridged Index Medicus
Journal Article
International journal of oncology, ISSN 1019-6439, 11/2017, Volume 51, Issue 5, pp. 1533 - 1540
Journal Article
Clinical Journal of the American Society of Nephrology, ISSN 1555-9041, 08/2012, Volume 7, Issue 8, pp. 1300 - 1309
Journal Article
The lancet oncology, ISSN 1470-2045, 2016, Volume 17, Issue 2, pp. 234 - 242
Journal Article
The lancet oncology, ISSN 1470-2045, 09/2014, Volume 15, Issue 10, pp. 1119 - 1128
Journal Article
Heart and vessels, ISSN 0910-8327, 3/2014, Volume 29, Issue 2, pp. 238 - 247
Bisoprolol fumarate (bisoprolol) is a β-blocker widely used to treat chronic heart failure (CHF). However, few studies have compared its efficacy and safety... 
Biomedical Engineering | Medicine & Public Health | Cardiac Surgery | Carvedilol | Japan | Vascular Surgery | Bisoprolol | Chronic heart failure | Cardiology | Randomized controlled trial | Left ventricular function | Cardiac & Cardiovascular Systems | Peripheral Vascular Disease | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Prospective Studies | Humans | Middle Aged | Patient Admission | Carbazoles - administration & dosage | Heart Failure - physiopathology | Male | Bisoprolol - adverse effects | Early Termination of Clinical Trials | Heart Rate - drug effects | Time Factors | Adrenergic beta-Antagonists - adverse effects | Female | Heart Failure - diagnosis | Adrenergic beta-Antagonists - administration & dosage | Heart Failure - mortality | Severity of Illness Index | Carbazoles - adverse effects | Double-Blind Method | Drug Administration Schedule | Ventricular Function, Left - drug effects | Stroke Volume - drug effects | Treatment Outcome | Propanolamines - adverse effects | Bisoprolol - administration & dosage | Heart Failure - drug therapy | Disease-Free Survival | Aged | Propanolamines - administration & dosage | Chronic Disease | Ventricular Remodeling - drug effects | Heart | Comparative analysis | Cardiac patients | Heart failure | Clinical trials | Comparative studies | Effectiveness | Beta blockers | Index Medicus
Journal Article